Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Cancer Research
|
June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy
Marka Crittenden, Michael Gough, John Chester, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
June 1, 2011
Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands
Changyu Zheng, Antonis Voutetakis, Benjamin Goldstein, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
September 29, 2004
Differences in F36VMpl-based in vivo selection among large animal models
Robert E Richard, R Angelo De Claro, James Yan, et al.
Molecular Cancer Therapeutics
|
April 13, 2011
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies
Joseph M Gozgit, Matthew J Wong, Scott Wardwell, et al.
Blood
|
August 30, 2002
Pharmacologically regulated in vivo selection in a large animal
Tobias Neff, Peter A Horn, Victor E Valli, et al.
Chemical Biology & Drug Design
|
November 1, 2011
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen
Sen Zhang, Frank Wang, Jeffrey Keats, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
Sant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Journal for Immunotherapy of Cancer
|
January 2, 2024
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Kurt A Jenkins, Miso Park, Magali Pederzoli-Ribeil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
Andrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Cancer Research
|
June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy
Marka Crittenden, Michael Gough, John Chester, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
June 1, 2011
Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands
Changyu Zheng, Antonis Voutetakis, Benjamin Goldstein, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
September 29, 2004
Differences in F36VMpl-based in vivo selection among large animal models
Robert E Richard, R Angelo De Claro, James Yan, et al.
Molecular Cancer Therapeutics
|
April 13, 2011
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies
Joseph M Gozgit, Matthew J Wong, Scott Wardwell, et al.
Blood
|
August 30, 2002
Pharmacologically regulated in vivo selection in a large animal
Tobias Neff, Peter A Horn, Victor E Valli, et al.
Chemical Biology & Drug Design
|
November 1, 2011
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen
Sen Zhang, Frank Wang, Jeffrey Keats, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
Sant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Journal for Immunotherapy of Cancer
|
January 2, 2024
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Kurt A Jenkins, Miso Park, Magali Pederzoli-Ribeil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
Andrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Page
of 6